Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of diffractive surface geometry on optical quality and halo formation in sinusoidal trifocal intraocular lenses.

Scientific reports·2026
Same author

Health effects of black and blond tobacco: a comparative analysis on smoking-related diseases with emphasis on bronchitis and COPD.

Frontiers in public health·2026
Same author

Ex Vivo Biodistribution of α-Lipoic Acid in the Eye Using Ocular Inserts: A Novel Strategy for Retinal Antioxidant Therapy.

Ophthalmology science·2026
Same author

Artificial Intelligence Driven Adjusted OCT-Based Classification System for Diabetic Macular Edema (AIDME).

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Structural analysis of rhodopsin states in megabody complexes.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Shedding Light on Halos: Quantifying the Impact of the Diffractive Profile in Multifocal Intraocular Lenses.

Translational vision science & technology·2026

Related Experiment Video

Updated: Jul 5, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Adalimumab therapy for refractory uveitis: a pilot study.

Manuel Diaz-Llopis1, Salvador García-Delpech, David Salom

  • 1Uveitis and Retina Unit, Department of Ophthalmology, University General Hospital of Valencia, Valencia, Spain. manuel.diaz@uv.es

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|May 15, 2008
PubMed
Summary
This summary is machine-generated.

Adalimumab effectively treated refractory autoimmune uveitis, improving vision and controlling inflammation in most patients. This therapy allowed for reduced immunosuppressant use and was generally well-tolerated, though relapses occurred.

Related Experiment Videos

Last Updated: Jul 5, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Autoimmune uveitis is a sight-threatening condition requiring effective treatment.
  • Refractory cases pose significant management challenges.
  • Adalimumab, a TNF-alpha inhibitor, has shown promise in inflammatory diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of adalimumab for treating refractory autoimmune uveitis.
  • To assess changes in visual acuity and intraocular inflammation.
  • To determine the potential for reducing concomitant immunosuppressive therapy.

Main Methods:

  • A prospective, noncomparative, nonrandomized clinical trial.
  • Nineteen patients received 40 mg subcutaneous adalimumab every other week for one year.
  • Outcome assessments included visual acuity, intraocular inflammation, and optical coherence tomography (OCT).

Main Results:

  • Visual acuity improved in 31% of eyes; intraocular inflammation was controlled in 63% of patients.
  • Cystoid macular edema (CME) resolved in 54.54% of affected eyes.
  • All patients reduced immunosuppressant doses by at least 50%; adalimumab was well-tolerated with minor injection site reactions.

Conclusions:

  • Adalimumab is an effective and safe option for managing refractory uveitis.
  • It facilitates a reduction in concomitant immunosuppressive drugs.
  • Long-term studies are needed to further confirm safety and efficacy in intraocular inflammation.